Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Exp Eye Res. 2017 Sep 30;165:175–181. doi: 10.1016/j.exer.2017.09.011

Fig. 2.

Fig. 2

Gene expression changes following treatment with AAV-STC-1. (A) Microarray analysis was performed in the P23H-1 (n=1) and the S334ter-4 (n=1) models and revealed a cohort of genes upregulated in both models. In the P23H-1 model, 133 genes were upregulated ≥2-fold. In the S334ter-4 model, 385 genes were upregulated ≥2-fold. 62 common genes were upregulated ≥2-fold in both P23H-1 and S334ter-4 models. In the P23H-1 model, 207 genes were downregulated ≥2-fold. In the S334ter-4 model, 518 genes were downregulated ≥2-fold. 9 common genes were downregulated ≥2-fold in both P23H-1 and S334ter-4 models (B) Genes of interest based on their function that were upregulated ≥2-fold in both models by microarray were selected for further analysis by quantitative real-time PCR (qPCR). Additionally, UCP-2 was also selected for further study. (C) qPCR revealed selected genes significantly upregulated (*P<0.05, **P<0.01, or ***P<0.005) in the S334ter-4 model (n=5).